Healthcare Dividend Stocks: The Recession-Proof Income Play for 2026

If a recession were to hit, it's a foregone conclusion that people won't stop taking their prescriptions, and they won't cancel major medical treatments.

24/7 Wall Street • Jan 10, 2026

AstraZeneca: Oncology Dominance Justifies New All-Time Highs

AstraZeneca started 2026 on a high note. On January 7, its stock reached an all-time high of $95.94. The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular franchises.

Seeking Alpha • Jan 10, 2026

Healthy Returns: What to expect from pharma at the JPM conference

At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.

CNBC • Jan 9, 2026

AstraZeneca names Rick Suarez head of US biopharmaceuticals unit

AstraZeneca on Thursday appointed company insider Rick Suarez as the head of its U.S. biopharmaceuticals unit to lead the drugmaker's previously announced $50 billion research, development and manufacturing investment in the country.

Reuters • Jan 8, 2026

Here's Why Astrazeneca (AZN) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Jan 8, 2026

Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know

Astrazeneca (AZN) concluded the recent trading session at $94.01, signifying a -1.21% move from its prior day's close.

Zacks Investment Research • Jan 9, 2026

Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit. Suarez will lead the execution of the Company's previously announced $50 billion US research, development and manufacturing investment, including construction of a $4.5 billion manufacturing facility in Virginia, AstraZeneca's largest single manufacturing investment globally. The investment underpins AstraZeneca's goal of generating $80.

Business Wire • Jan 8, 2026

JP Morgan expects solid AstraZeneca quarter and reassuring outlook

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) is set to deliver a solid finish to 2025 when it reports fourth-quarter results next month, according to JP Morgan, which expects earnings to come in modestly ahead of market expectations and guidance for 2026 to underpin confidence in the growth outlook. The US bank forecasts fourth-quarter revenues of $15.5 billion, representing 2% growth at constant exchange rates and about 1% ahead of consensus forecasts.

Proactive Investors • Jan 6, 2026

Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Jan 6, 2026

BostonGene and AstraZeneca Announce Strategic Collaboration to Advance Foundation Model-Driven Oncology Development

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with AstraZeneca, a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, to advance oncology drug development using BostonGene's multimodal AI platform. The collaboration leverages BostonGene's foun.

Business Wire • Jan 6, 2026